Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2023

27.10.2022 | Original Article

Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)

verfasst von: Junki Takenaka, Shiro Watanabe, Takashige Abe, Kenji Hirata, Yuko Uchiyama, Rina Kimura, Nobuo Shinohara, Kohsuke Kudo

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Pheochromocytomas and paragangliomas (PPGLs) are rare tumors arising from the neural crest cells that form the sympathetic and parasympathetic nervous systems. Radiotherapy with [131I]metaiodobenzylguanidine (MIBG) is recommended for unresectable PPGLs. We investigated the usefulness of the metabolic tumor volume (MTV) and total lesion glycolysis (TLG) derived from [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) for predicting the prognosis of patients with unresectable PPGL(s) before receiving [131I]MIBG therapy.

Patients and methods

We retrospectively analyzed the cases of 25 patients with unresectable PPGLs treated with [131I]MIBG at our hospital between 2001 and 2020. The MTV and TLG were measured in reference to liver accumulation. We divided the patients into two groups based on median values for the maximum standardized uptake value (SUVmax), MTV, and TLG, and evaluated between-group differences using log-rank tests. Cox proportional hazards models were used to determine whether there were significant differences in prognosis with respect to tumor type (pheochromocytoma vs. paraganglioma), site of metastasis, age, past treatment (chemotherapy, external radiation or [131I]MIBG treatment before the current [131I]MIBG treatment), urinary catecholamine, SUVmax, MTV, and TLG.

Results

The median follow-up time was 42 months (range 2–136 months). The median overall survival was 63 months. The overall survival (OS) was significantly shorter in the high-MTV group (log-rank test, p = 0.049) and the high-TLG group (p = 0.049), with no significant difference between the high- and low-SUVmax groups (p = 0.19). Likewise, there was no significant difference in prognosis according to pheochromocytoma or paraganglioma, metastasis location, age, or prior chemotherapy. A history of external radiation before [131I]MIBG treatment was associated with a significantly worse prognosis (hazard ration [HR] = 7.95, p = 0.0018). Urinary adrenaline and noradrenaline were not significant prognostic factors (p = 0.70, p = 0.25, respectively), but urinary dopamine did predict a worse outcome (p = 0.022). There was no increased risk of death for higher SUVmax or TLG (p = 0.63 and 0.057, respectively), but higher MTV did predict a worse outcome (HR = 7.27, p = 0.029).

Conclusion

High MTV and high TLG were significantly associated with a poor prognosis after [131I]MIBG therapy for PPGLs. Other treatment strategies for such patients may need to be explored.
Literatur
1.
Zurück zum Zitat Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33:90–114.CrossRef Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol. 2022;33:90–114.CrossRef
2.
Zurück zum Zitat Choi YM, Sung T-Y, Kim WG, Lee JJ, Ryu J-S, Kim TY, et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. J Surg Oncol. 2015;112:815–21.CrossRef Choi YM, Sung T-Y, Kim WG, Lee JJ, Ryu J-S, Kim TY, et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. J Surg Oncol. 2015;112:815–21.CrossRef
3.
Zurück zum Zitat Ezzat Abdel-Aziz T, Prete F, Conway G, Gaze M, Bomanji J, Bouloux P, et al. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes. J Surg Oncol. 2015;112:486–91.CrossRef Ezzat Abdel-Aziz T, Prete F, Conway G, Gaze M, Bomanji J, Bouloux P, et al. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes. J Surg Oncol. 2015;112:486–91.CrossRef
4.
Zurück zum Zitat Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476–90.CrossRef Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476–90.CrossRef
5.
Zurück zum Zitat van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EPM. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80:487–501.CrossRef van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EPM. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80:487–501.CrossRef
6.
Zurück zum Zitat Timmers HJLM, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262–9.CrossRef Timmers HJLM, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262–9.CrossRef
7.
Zurück zum Zitat Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700–8.CrossRef Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700–8.CrossRef
8.
Zurück zum Zitat Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging. 2011;38:1869–75.CrossRef Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging. 2011;38:1869–75.CrossRef
9.
Zurück zum Zitat Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, et al. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35:1223–31.CrossRef Uchiyama Y, Hirata K, Watanabe S, Okamoto S, Shiga T, Okada K, et al. Development and validation of a prediction model based on the organ-based metabolic tumor volume on FDG-PET in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2021;35:1223–31.CrossRef
10.
Zurück zum Zitat Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao C-T, Yen T-C. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.CrossRef Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao C-T, Yen T-C. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.CrossRef
11.
Zurück zum Zitat Xie M, Wu K, Liu Y, Jiang Q, Xie Y. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32:446.CrossRef Xie M, Wu K, Liu Y, Jiang Q, Xie Y. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32:446.CrossRef
12.
Zurück zum Zitat Yoo SW, Kim J, Chong A, Kwon S-Y, Min J-J, Song H-C, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging. 2012;46:286–93.CrossRef Yoo SW, Kim J, Chong A, Kwon S-Y, Min J-J, Song H-C, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging. 2012;46:286–93.CrossRef
13.
Zurück zum Zitat Hirata K, Kobayashi K, Wong K-P, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9: e105682.CrossRef Hirata K, Kobayashi K, Wong K-P, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9: e105682.CrossRef
14.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.CrossRef Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150.CrossRef
15.
Zurück zum Zitat Zheng L, Gu Y, Silang J, Wang J, Luo F, Zhang B, et al. Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with malignant pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2021;12: 684668.CrossRef Zheng L, Gu Y, Silang J, Wang J, Luo F, Zhang B, et al. Prognostic nomograms for predicting overall survival and cancer-specific survival of patients with malignant pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne). 2021;12: 684668.CrossRef
16.
Zurück zum Zitat Eisenhofer G, Lenders JWM, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739–49.CrossRef Eisenhofer G, Lenders JWM, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739–49.CrossRef
17.
Zurück zum Zitat Zhong X, Ye L, Su TW, Xie J, Zhou W, Jiang Y, et al. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2017;87:127–35.CrossRef Zhong X, Ye L, Su TW, Xie J, Zhou W, Jiang Y, et al. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2017;87:127–35.CrossRef
18.
Zurück zum Zitat van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SWJ, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol. 2002;147:85–94.CrossRef van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SWJ, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol. 2002;147:85–94.CrossRef
19.
Zurück zum Zitat Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717–25.CrossRef Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717–25.CrossRef
20.
Zurück zum Zitat Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–64.CrossRef Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–64.CrossRef
21.
Zurück zum Zitat Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol. 1999;12:1107–11. Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol. 1999;12:1107–11.
22.
Zurück zum Zitat Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505–9.CrossRef Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505–9.CrossRef
23.
Zurück zum Zitat Ayala-Ramirez M, Palmer JL, Hofmann M-C, de la Cruz M, Moon BS, Waguespack SG, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98:1492–7.CrossRef Ayala-Ramirez M, Palmer JL, Hofmann M-C, de la Cruz M, Moon BS, Waguespack SG, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98:1492–7.CrossRef
24.
Zurück zum Zitat Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36:267–78.CrossRef Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, et al. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2022;36:267–78.CrossRef
25.
Zurück zum Zitat Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, et al. Effects of repeated 131I-meta-iodobenzylguanidine radiotherapy on tumor size and tumor metabolic activity in patients with metastatic neuroendocrine tumors. J Nucl Med. 2021;62:685–94.CrossRef Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, et al. Effects of repeated 131I-meta-iodobenzylguanidine radiotherapy on tumor size and tumor metabolic activity in patients with metastatic neuroendocrine tumors. J Nucl Med. 2021;62:685–94.CrossRef
Metadaten
Titel
Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)
verfasst von
Junki Takenaka
Shiro Watanabe
Takashige Abe
Kenji Hirata
Yuko Uchiyama
Rina Kimura
Nobuo Shinohara
Kohsuke Kudo
Publikationsdatum
27.10.2022
Verlag
Springer Nature Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2023
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01798-6

Weitere Artikel der Ausgabe 1/2023

Annals of Nuclear Medicine 1/2023 Zur Ausgabe